Quintrio
Home

Stock overview

IceCure Medical Ltd. Ordinary Shares

ICCM

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.74 – $0.81
Volume 76,092
Market cap $4M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for ICCM.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for ICCM.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Kyntra Bio (KYNB) Reports Q3 Loss, Misses Revenue Estimates

Kyntra Bio reported a quarterly loss of $3.42 per share, beating consensus estimates of $3.66 loss, representing a 6.56% earnings surprise. However, revenues of $1.76 million missed estimates by 10.38%. The stock has declined 60.8% year-to-date versus the S&P 500's 10.5% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

Zacks Investment Research

HeartFlow (HTFL) Reports Q3 Loss, Beats Revenue Estimates

HeartFlow (HTFL) reported a quarterly loss of $0.03 per share, beating consensus estimates of $0.10 loss, with a 70% earnings surprise. Revenue of $72.86 million exceeded expectations by 11.92%. The stock has gained 102.7% year-to-date but received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

Zacks Investment Research

Natera (NTRA) Reports Q3 Loss, Beats Revenue Estimates

Natera (NTRA) reported a quarterly loss of $0.39 per share, significantly worse than the consensus estimate of $0.17 loss, representing a -129.41% earnings surprise. While the company beat revenue expectations at $793.98 million versus estimates, it has only surpassed EPS estimates once in the last four quarters. The stock received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends, suggesting underperformance ahead despite the stock's 70.7% year-to-date gain.

Benzinga

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

IceCure Medical Ltd. (NASDAQ: ICCM) announced a $5.5 million private placement of 1.83 million ordinary shares and warrants priced at $3.00 per share, representing a premium to the previous closing price. The offering is expected to close on June 18, 2026, with proceeds intended for working capital and general corporate purposes. The company also agreed to amend previously issued warrants to reduce their exercise price from $16.50 to $3.00 per share, subject to shareholder approval.

Benzinga

IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance

IceCure Medical reported a 70% increase in its U.S. active commercial install base for ProSense® breast cancer cryoablation systems following FDA marketing authorization in October 2025. The growth is driven by FDA clearance, clinical guideline support from the American Society of Breast Surgeons, increased physician demand demonstrated at major medical conferences, and growing patient awareness through media coverage. The company believes it is in the early stages of a significant commercial opportunity in the U.S. market.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 4, 20261-for-30reverse split